- Home
- EFSH vs GTBP Comparison
EFSH vs GTBP Comparison
Compare EFSH & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSH
- GTBP
- Stock Information
- Founded
- EFSH 1948
- GTBP 1965
- Country
- EFSH United States
- GTBP United States
- Employees
- EFSH N/A
- GTBP N/A
- Industry
- EFSH Professional Services
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- EFSH Consumer Discretionary
- GTBP Health Care
- Exchange
- EFSH Nasdaq
- GTBP Nasdaq
- Market Cap
- EFSH 4.2M
- GTBP 4.9M
- IPO Year
- EFSH N/A
- GTBP N/A
- Fundamental
- Price
- EFSH $0.15
- GTBP $2.15
- Analyst Decision
- EFSH
- GTBP Strong Buy
- Analyst Count
- EFSH 0
- GTBP 1
- Target Price
- EFSH N/A
- GTBP $11.00
- AVG Volume (30 Days)
- EFSH 2.7M
- GTBP 28.3K
- Earning Date
- EFSH 04-16-2025
- GTBP 03-25-2025
- Dividend Yield
- EFSH N/A
- GTBP N/A
- EPS Growth
- EFSH N/A
- GTBP N/A
- EPS
- EFSH N/A
- GTBP N/A
- Revenue
- EFSH $69,415,140.00
- GTBP N/A
- Revenue This Year
- EFSH N/A
- GTBP N/A
- Revenue Next Year
- EFSH N/A
- GTBP N/A
- P/E Ratio
- EFSH N/A
- GTBP N/A
- Revenue Growth
- EFSH 228.22
- GTBP N/A
- 52 Week Low
- EFSH $0.15
- GTBP $1.72
- 52 Week High
- EFSH $717.62
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- EFSH 38.07
- GTBP 44.49
- Support Level
- EFSH $0.15
- GTBP $2.07
- Resistance Level
- EFSH $0.17
- GTBP $2.29
- Average True Range (ATR)
- EFSH 0.02
- GTBP 0.19
- MACD
- EFSH 0.04
- GTBP 0.01
- Stochastic Oscillator
- EFSH 0.00
- GTBP 34.07
About EFSH 1847 Holdings LLC
1847 Holdings LLC is a diversified holding company. It operates in Four segments: Retail and appliances, Retail and Eyewear, Construction, and Automotive Supplies. The company generates maximum revenue from the Construction segment. The firm, through its subsidiaries, provides a wide range of land application services and sells equipment and parts, primarily to the agricultural, construction, and lawn and garden industries.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.